Novel farnesyl protein transferase inhibitors as antitumor agents
申请人:Schering Corporation
公开号:US20040122018A1
公开(公告)日:2004-06-24
Disclosed are novel tricyclic compounds represented by the formula (1.0):
1
and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
The present invention relates to stereoisomerically enriched phosphorus compounds, transition metal catalysts which can be prepared therefrom and their use in stereoselective catalytic processes, and also a process for preparing the stereoisomerically enriched phosphorus compounds.
Catalysts prepared from [Rh(2)(mu(2)-Cl)(2)(C(2)H(4))(4)] and (S)-4 have allowed the efficient enantioselective 1,4-addition of arylboronic acids to alpha,beta-unsaturated carbonyls (Hayashi-Miyaura reaction) (5-0.1 mol % catalyst, up to 95% ee). The iridium complex (S,S)-[Ir((Ph)tropp(Ph))(2)]OTf ((S,S)-6; OTf=SO(3)CF(3)) has been used as a catalyst in the hydrogenation of various nonfunctionalized
Die vorliegende Erfindung betrifft stereoisomerenangereicherte Phosphorverbindungen der Formel (I)
daraus herstellbare Übergangsmetallkatalysatoren und deren Anwendung in stereoselektiven katalytischen Prozessen, sowie ein Verfahren zur Herstellung der stereoisomerenangereicherten Phosphorverbindungen.